Stryker touts NEJM publication of Trevo thrombectomy device trial results

Stryker (NYSE:SYK) yesterday released results from the Dawn trial of its Trevo thrombectomy device, touting significant effects even when used beyond six hours after stroke. Results from the trial were published in the New England Journal of Medicine, the Kalamazoo, Mich.-based company said. “By quadrupling the size of the therapeutic time window, the consequence of Dawn is that many more patients with large vessel occlusion stroke have the potential to be treated with mechanical thrombectomy.  Dawn validates the physiological, rather than time-based approach to patient selection for endovascular therapy,” co-principal investigator Dr. Tudor Jovin of the University of Pittsburgh Medical Center said in a prepared statement. In the Dawn trial, researchers compared treatment using the Trevo thrombectomy device in addition to clot-busting drugs with the drugs alone between 6 and 24 hours after stroke patient was last known to be well. Results indicated that patients treated with the thrombectomy device within six to 24 hours after stroke had better disability and functional independence outcomes at 90 days when compared to standard medical care. “For every two patients who underwent thrombectomy, one additional patient had a better score for disability at 90 days (as compared with the results in the control group); for every 2.8 patients who underwent thrombectomy, 1 additional patient had functional independence at 90 days,” researchers wrote in the st...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Vascular Stryker Source Type: news